Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 27, 2023 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 5.07   Submission of Matters to a Vote of Security Holders (a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 27, 2023. (b) Shareholders voted on the matters set forth below. 1. The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 16, 2023 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes: Nominee Votes For  Votes Against Abstentions Broker non-vote Ronald E. Blaylock 3,789,612,837 83,839,363 12,467,881 822,779,764 Albert Bourla 3,653,674,437 208,682,127 23,564,504 822,779,764 Susan Desmond-Hellmann 3,828,773,799 46,025,527 11,121,794 822,779,764 Joseph J. Echevarria 3,778,999,117 94,432,165 12,489,838 822,779,764 Scott Gottlieb 3,842,319,407 32,995,098 10,606,615 822,779,764 Helen H. Hobbs 3,785,122,522 89,855,218 10,943,380 822,779,764 Susan Hockfield 3,844,758,007 29,938,558 11,222,555 822,779,764 Dan R. Littman 3,820,810,803 52,740,318 12,369,605 822,779,764 Shantanu Narayen 3,834,990,965 38,626,491 12,303,663 822,779,764 Suzanne Nora Johnson 3,647,540,160 226,795,872 11,585,088 822,779,764 James Quincey 3,793,804,997 79,619,976 12,495,108 822,779,764 James C. Smith 3,759,605,435 114,075,438 12,240,247 822,779,764 2. The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was approved based upon the following votes: Votes for approval 4,476,884,380 Votes against 216,080,165 Abstentions 15,730,121 Broker non-votes n/a 3. The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers was approved based upon the following votes : Votes for approval 3,579,314,991 Votes against 278,786,983 Abstentions 27,817,386 Broker non-votes 822,779,764 4. The proposal on the advisory vote on the frequency of future advisory votes to approve executive compensation received the following votes: For 1 year 3,766,703,452 For 2 years 14,391,226 For 3 years 89,089,799 Abstentions 15,686,294 Broker non-votes 822,779,764 5. The shareholder proposal regarding ratification of termination pay was not approved based upon the following votes: Votes for approval 383,373,901 Votes against 3,471,502,220 Abstentions 31,042,621 Broker non-votes 822,779,764 6. The shareholder proposal regarding independent board chairman policy was not approved based upon the following votes: Votes for approval 1,341,494,540 Votes against 2,522,043,083 Abstentions 22,383,108 Broker non-votes 822,779,764 7. The shareholder proposal regarding transfer of intellectual property to potential COVID-19 manufacturers feasibility report was not approved based upon the following votes: Votes for approval 466,014,359 Votes against 3,345,078,090 Abstentions 74,828,282 Broker non-votes 822,779,764 8. The shareholder proposal regarding impact of extended patent exclusivities on product access report was not approved based upon the following votes: Votes for approval 1,152,896,529 Votes against 2,665,474,921 Abstentions 67,549,520 Broker non-votes 822,779,764 9. The shareholder proposal regarding political contributions congruency report was not approved based upon the following votes: Votes for approval 539,212,248 Votes against 3,275,597,231 Abstentions 71,110,795 Broker non-votes 822,779,764 (c) Not applicable. (d) Based upon the results set forth in item (b) (4) above, and consistent with the Board's recommendation, the Board of Directors has determined that advisory votes on executive compensation will be submitted to shareholders on an annual basis until the next required vote on the frequency of such votes. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   PFIZER INC.               By: /s/ Margaret M. Madden   Margaret M. Madden     Senior Vice President and Corporate Secretary     Chief Governance Counsel       Dated: May 1, 2023